This clinical trial is focused on studying the effects of a medication called Povorcitinib on a skin condition known as vitiligo. Vitiligo is a condition where patches of skin lose their color, and this study specifically looks at a type called nonsegmental vitiligo, which is the most common form. The purpose of the study is to compare the effectiveness of Povorcitinib to a placebo in treating this condition over a period of 52 weeks.

Participants in the study will be randomly assigned to receive either Povorcitinib or a placebo. The study is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving the actual medication and who is receiving the placebo. This helps ensure that the results are not biased. The medication is taken orally in the form of a tablet.

The study will last for about a year, during which participants will be monitored to see if there is an improvement in their vitiligo. The main goal is to see if participants achieve a significant improvement in their skin condition by the end of the study. Participants will have regular check-ups and assessments to track their progress and ensure their safety throughout the trial.